Velicept Therapeutics, Inc.

Urovant Sciences, Inc. ’s oral beta-3 agonist vibegron has missed its primary endpoint in a Phase IIa study in the treatment of irritable bowel syndrome (IBS) pain. The news comes as Urovant awaits th

Fountain Healthcare Partners of Ireland has put together its third life sciences fund, raising €125m -exceeding its initial target of €100m - and earmarked most of it for European companies. The new f

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

IN VITRO DIAGNOSTICS AltheaDx Inc. AltheaDx 's Series C brings in $30mm AltheaDx Inc. (oncology R&D services and personalized medicine focused on cardio, neuro, and blood disorders) brought in